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ABSTRACT
Objectives: An attempt was made to demonstrate the superiority of the treatment model using continuous subcutaneous 
insulin infusion (CSII) over multiple daily injections (MDI) of insulin in achieving a successful pregnancy outcome and good 
newborn’s condition in patients with type 1 diabetes.
Material and methods: The study included 297 infants born to type 1 diabetic patients; 175 patients were treated with 
MDI and 122 with CSII. 
Maternal metabolic control during pregnancy, gestational weight gain, insulin requirements, pregnancy outcome and 
neonatal status were compared between MDI and CSII arm.
The composite adverse neonatal outcome was diagnosed if at least one of the following was found: abnormal birth weight 
(LGA or SGA), congenital malformation, miscarriage, intrauterine fetal death, emergency CS due to fetal risk, iatrogenic 
prematurity, RDS, hypoglycemia, hyperbilirubinemia, and the postpartum pH in the umbilical artery ≤ 7.1.
Results: The studied groups did not differ regarding gestational week at delivery, a proportion of births at full term, preterm 
births, miscarriages, or late pregnancy losses (intrauterine fetal death > 22 weeks). Newborns of mothers treated with CSII 
showed lower incidence of neonatal complications (composite adverse neonatal outcome) compared to those of mothers 
treated with MDI (60% vs 74%, respectively; p = 0.01). We did not find any association between the mode of treatment and 
composite adverse maternal outcome.
Conclusions: The use of CSII in the treatment of pregnant women with type 1 diabetes was associated with reduced 
number of neonatal complications presented as neonatal composite outcome but had no influence on maternal outcome.
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INTRODUCTION
Short after insulin introduction, perinatal mortality of 
newborns among mothers with type 1 diabetes (T1DM) 
reached 40%. In the 1980s, it dropped to 5% in the most 
advanced centers due to modern medical treatments, with 
a further reduction to 1–2% that is reported today [1]. Apart 
from this substantial improvement, pregnancy in women 
with type 1 diabetes is still associated with an elevated feto- 
maternal risk. Unfortunately, we are still far from pregnancy 
outcomes in patients with T1DM being comparable to the 
general population.
The number of miscarriages and birth defects in the 
diabetic population remains 2 to 4 times higher than in 
the healthy population [2–5]. Maternal hyperglycemia in 
later pregnancy is a risk factor for late intrauterine fetal 
death, which is 2 to 5 times higher than in the rest of the 
population. Moreover, small vessels disease, characteristic 
for long-lasting diabetes also induces changes in placental 
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micro vessels, resulting in placental insufficiency that also 
contributes to an increased proportion of fetal demise [6]. 
Fetal macrosomia, occurring in 25–42% of newborns, is 
a consequence of increased glucose and lipid transfer and 
selective transport of amino acids through the placenta in 
the second half of pregnancy. Subsequent fetal hyperin-
sulinemia results in hypertrophy and hyperplasia of fetal 
cells [7]. Fetal hyperinsulinemia also inhibits the stimulat-
ing effects of cortisol and lowers lecithin levels, resulting in 
an impaired synthesis of surfactant and causing delayed 
fetal lung maturation. This impairment can manifest as res-
piratory distress syndrome (RDS) that occurs 4 to 6 times 
more often in that group of neonates and can also happen 
in deliveries at term. RDS coexists with other symptoms of 
diabetic fetopathy: hypoglycemia, polycythemia, and hyper-
bilirubinemia [8]. New data also link maternal diabetes to 
remote health risks in the offspring such as type 2 diabetes 
and obesity in later life, by altering intrauterine develop-
ment and growth [9]. 
Objectives
An attempt was made to demonstrate the superiority 
of the treatment model using continuous subcutaneous 
insulin infusion (CSII) over multiple daily injections (MDI) 
of insulin in achieving a successful pregnancy outcome and 
good newborn’s condition in patients with type 1 diabetes.
MATERIAL AND METHODS
A retrospective analysis based on medical records of the 
pregnancies and their outcome, and neonates born from 
297 pregnant women with T1DM. Patients who developed 
type 1 diabetes at least one year before conception, with 
single pregnancy and were given obstetric care before the 
15th week of gestation were included in the study. Partici-
pants were referred from local diabetic units for antenatal 
care with a diagnosis of type 1 diabetes set at a baseline by 
practitioners who initiated medical therapy. For perinatal 
risk assessment, we used modified White’s classification of 
diabetes during pregnancy [10]. We compared the course 
of pregnancy, pregnancy outcome, and the newborn status 
in both groups, taking into account the efficacy of the two 
investigated treatment methods.
All patients were treated with functional intensive insu-
lin therapy using recombinant human insulins or short-act-
ing insulin analogues according to the uniform procedure 
of the study center. 
We allocated our patients to two groups, according to 
the type of insulin therapy used:
1. The group of patients treated with multiple daily insulin 
injections; N = 175.
2. The group of patients treated with continuous subcu-
taneous insulin infusion; N = 122.
Each patient referred to the unit in early pregnancy be-
tween 2010 to 2015 for further antenatal care, was offered 
to continue MDI or to participate in appropriate training 
on CSII. In patients who completed the training, we com-
menced treatment with CSII. None of the participants used 
the continuous glucose monitoring system (CGMS).
According to the center’s protocol, the patients were 
hospitalized at least once during each trimester and were 
also seen in the outpatient clinic for combined diabetes and 
obstetrics antenatal care, which enabled data collection 
throughout the entire pregnancy.
We used the following criteria for good diabetes 
control during pregnancy: glycated hemoglobin ≤ 6.1% 
(43 mmol/mol), fasting glucose 60–90 mg/dL (3.3–5.0 mmol/L), 
glycemia one hour after a meal < 120mg/dL (6.7 mmol/L) 
and nocturnal glycemia > 60 mg/dL (3.3 mmol/L), in ac-
cordance to the recommendations of the Polish Diabetes 
Association (PTD) of 2011 [11]. Patients kept self-monitoring 
diaries with commercially available glucometers determin-
ing capillary blood glucose levels. We diagnosed hypogly-
cemic events if glucose concentration was below 40 mg/dL 
(2.2 mmol/L). Postprandial hyperglycemia was defined as 
a glycemia above 140 mg/dL (7.8 mmol/L) one hour after 
a meal.
We retrieved the following pieces of information from 
medical notes of the participants: patient age, age at diabe-
tes onset, duration of illness, gestational age and body mass 
index (BMI) at the first antenatal visit, number of previous 
births, vascular complications like nephro- and retinopathy, 
and prepregnancy hypertension.
In subsequent trimesters, we monitored selected bio-
chemical parameters evaluated at the Central Laboratory 
of the Hospital and daily glucose profiles performed by 
patients using glucometers for self-control during hospi-
talization.
From the medical records, we retrieved the following 
feto-maternal pregnancy outcomes: gestational age at de-
livery, mode of delivery, indications for caesarean sections, 
miscarriages and intrauterine deaths after 22nd gestational 
week. Women who lost their pregnancies within four weeks 
after enrollment were excluded from the analysis.
In newborns, we analyzed: birth weight, Apgar score at 
1 and 5 minutes, pH from umbilical artery, birth weight (LGA; 
birthweight > 90th percentile according to local growth 
charts for normal population, customized for gestational 
age at delivery and sex; SGA; birthweight < 10th percentile 
according to local growth charts for normal population, 
customized for gestational age at delivery and sex). We 
also recorded RDS, hyperbilirubinemia, hypoglycemia, and 
congenital malformations.
We defined the following abnormalities as malforma-
tions: cardiovascular defects (ventricular septal defect (VSD) 
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and atrial septal defect (ASD), transposition of the great 
arteries (TGA), and coarctation of the aorta), caudal regres-
sion syndrome, and defects of the neural tube in the form 
of encephalocele [12]. We did not include newborns who 
have been diagnosed with patent foramen ovale because 
its prevalence was similar to this seen in the general popula-
tion. Therefore, it could not be attributed to the maternal 
disease [13].
We defined a composite adverse neonatal outcome 
as abnormal birth weight (LGA or SGA), presence of con-
genital malformation, miscarriage, intrauterine fetal death, 
emergency CS due to fetal risk, iatrogenic prematurity, RDS, 
hypoglycemia, hyperbilirubinemia, and the postpartum pH 
in the umbilical artery ≤ 7.1 [14].
The composite adverse maternal outcome was recorded 
if at least one of the following occurred: newly diagnosed 
gestational hypertension, preeclampsia, emergency cc due 
to maternal risk, a progression of vascular complications 
or diagnosis of vascular complications de novo, excessive 
gestational weight gain.
For the statistical analysis, we used tests appropriate 
for the distribution of the variables. Quantitative variables 
with normal distribution were presented as mean ± SD or as 
median with minimum and maximum values for variables 
with nonparametric distribution. The chi² test was used 
to compare the characteristics of the unrelated nominal 
variables. The Mann-Whitney test was used to compare the 
unrelated ordinal values. Logistic regression models were 
made to demonstrate the significance of the impact of the 
independent parameters on the occurrence of the studied 
endpoint. A relative risk analysis was performed to compare 
the two treatment methods. P values below 0.05 were con-
sidered significant. Statistical calculations were performed 
using Microsoft Excel 2010, Statistica 7.1, and SPSS 14.0.
RESULTS
Characteristics of participants did not show statistically 
significant differences in age, the onset of care, or baseline 
BMI between the groups. Pregnant women in the CSII arm 
were significantly younger when diagnosed with T1DM, had 
a significantly longer history of the disease and were signifi-
cantly more likely to plan their pregnancies, comparing to 
the MDI arm. The CSII- group also included significantly more 
patients with long-lasting diabetes with vascular changes 
in comparison to the MDI group. (Tab. 1).
Daily insulin requirements and gestational weight gain 
were similar between the groups. We observed an improve-
ment in metabolic control regardless of the type of therapy. 
A longitudinal analysis of HbA1c showed a significant reduc-
tion in this parameter across the trimesters, irrespectively of 
the method of treatment. Also, mean daily glucose levels, 
fasting, postprandial and nocturnal glycemia improved in 
both arms. It is notable that fasting and nocturnal glycemia 
in the CSII group remained in the target range according 
to recommendations, but the results of MDI patients were 
higher [11]. We did not find differences in the number of 
hypoglycemic episodes during pregnancy among pregnant 
women from both groups. However, CSII treatment was as-
sociated with a significantly lower incidence of postprandial 
hyperglycemia in the second (15% vs 4.5%) and in the third 
(22.5% vs 7.7%) trimester compared to the MDI group (Tab. 2).
The studied groups did not differ regarding gestational 
week at delivery, a proportion of births at full term, preterm 
births, miscarriages, or late pregnancy losses. However, we 
noted a trend for the increased number of preterm births 
and intrauterine deaths in MDI arm (Tab. 3). In our cohort, 
we evaluated the composite adverse neonatal outcome be-
tween the groups and noted significantly reduced propor-
tion of neonatal complications in the CSII group (p < 0.01) 
(Tab. 4). Maternal age, participant age when diagnosed 
with the disease and pregnancy planning (characteristics 
that differed significantly between the MDI and CSII groups, 
see Table 1) did not significantly correlate with composite 
neonatal outcome. Birth weight and Apgar scores were 
not statistically different, but we noted a trend for a higher 
first-minute Apgar score in CSII arm.
In the logistic regression model, we confirmed that dura-
tion of diabetes, the first-trimester body weight, glycated 
haemoglobin in the first and second trimesters, and insulin 
requirement in the last trimester were significant predictors 
Table 1. Characteristics of the studied groups
Analyzed parameter MDIN = 175
CSII
N = 122 p
Age of the pregnant 
woman [years] 28.0 ± 4.9 27.9 ± 4.5 0.96*
Disease onset [years] 17.9 ± 8.2 14.5 ± 6.9 0.001*
Diabetes duration [years] 10.2 ± 6.8 13.5 ± 8.4 0.0004*
Onset of diabetes care [w.g.] 7.7 ± 2.6 7.4 ± 2.4 0.40*
Body weight at the beginning 
of care [kg] 67.1 ± 13.2 65.8 ± 11.3 0.58*
Weight gain during pregnancy 
[kg] 12.58 12.06 0.50*
BMI at the beginning of care 
[kg/m2] 24.5 ± 4.5 23.8 ± 3.4 0.31*
Patients planning pregnancy 
[N; %] 55 (30) 55(45) 0.02**
Patients with nephropathy 
[N; %] 13 (7) 13 (11) 0.33**
Patients with diabetic 
retinopathy [N; %] 25 (14) 20 (16) 0.62**
Patients with chronic 
hypertension [N; %] 19 (11) 12 (10) 0.77**
* Mann-Whitney test, ** Chi2 test
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of excessive fetal birth weight in the studied population 
(Tab. 5). In a separate analysis the proportion of LGA new-
borns was similar between the arms.
Late pregnancy loss (intrauterine death) occurred in five 
patients in the studied population. Four cases recorded in 
the MDI arm occurred in patients with an inadequate meta-
bolic control throughout the whole pregnancy (mean HbA1c 
in a subgroup of 9.7%) or noncomplying (not reporting for 
scheduled antenatal check-ups in the referral center). A sin-
gle case noted in the CSII arm occurred in a well-controlled 
woman with long-lasting diabetes and coexisting diabetic 
kidney disease which is an independent risk factor for un-
favorable neonatal outcome.
We did not note any association between the mode of 
treatment end composite adverse maternal outcome.
DISCUSSION
Hormonal changes, mainly increasing concentrations 
of anti-insulin factors, can lead to significant fluctuations in 
glucose levels, even in patients whose metabolism is con-
sidered well-controlled before pregnancy. Moreover, during 
normal pregnancy maternal body operates on lower glucose 
levels due to natural hormonal adaptations that give a fetus 
a priority in an access to maternal glucose [15]. Therefore, 
close monitoring of both maternal and fetal well-being is 
mandatory, as there is a higher risk of miscarriage, con-
genital malformations, early and late intrauterine death, and 
fetal growth disorders that can occur even at nearly normal 
glycemic levels [10, 11, 16].
The current standards concerning antenatal care for 
women with diabetes recommend the use of intensive 
functional insulin therapy in this population. Taking into 
account the patient’s clinical condition, technical ability, 
and compliance, we have two options for administering 
insulin: using MDI or CSII.
Carbohydrate metabolism changes in the pregnant 
woman and the pregnancy itself becomes a diabetogenic 
factor, altering the hormonal homeostasis. There is a worsen-
ing of carbohydrate tolerance, increased peripheral insulin 
resistance, and thus impaired action of exogenous insulin 
[17, 18]. Pregnant women must be aware, however, that 
continuous adding extra insulin doses to achieve normo-
Table 2. Metabolic control of patients in both studied groups
Analyzed parameter MDIN = 175
CSII
N = 122 p






56 ± 15.4 0.61*
Postprandial 
hyperglycemia ≥ 140 mg/dL 
[N; %]
110 (27)*** 86 (27.5)*** 0.68**






42 ± 10 0.97*
Postprandial 
hyperglycemia ≥ 140 mg/dL 
[N; %]
53 (15)*** 14 (4.5)*** 0.0001**






45 ± 8 0.67*
Postprandial 
hyperglycemia ≥ 140 [mg/dL] 64 (22.5)*** 21 (7.7)*** 0.0001**
* Mann-Whitney test, ** Chi2 test, *** % calculated for the number of all 
measurements from a given group in a given trimester. 
In the second trimester, calculations were made for MDI N = 165, CSII 
N = 120 (miscarriage excluded) and in the third trimester, calculations were 
made for MDI N = 161, CSII N = 119 (intrauterine death excluded)
Table 3. Pregnancy outcome
Analyzed parameter MDIN = 175
CSII
N = 122 p
Gestational age at delivery [w.g.] 37.5 ± 2.0 37.5 ± 1.9 0.63*
Births at full term [N; %] 131 (73) 95 (77.5) 0.64*
Late preterm births: GA 34–37 [N; %] 17 (9) 19 (15.5) 0.18*
Preterm births: GA ≤ 33 + 6 [N; %] 13 (7) 5 (4) 0.35*
Miscarriages: GA < 22 [N; %] 10 (9) 2 (2) 0.15*
Intrauterine deaths below 22nd 
gestational week [N; %] 4 (2) 1 (1) 0.90*
* Chi2 test
Table 4. Status of newborns
Analyzed parameter MDIN = 161
CSII
N = 119 p
Birth weight [g] 3480 ± 750 3430 ± 680 0.58*
Apgar score in the first min. of 
life [median, min-max] 8 [1–10] 8 [1–10] 0.06*
Apgar score in the fifth min. of 
life [median, min-max] 9 [1–10] 9 [1–10] 0.38*
Composite adverse neonatal 
outcome [N; %] 119 (74) 72 (60) 0.01**
Miscarriages and intrauterine death excluded from the analysis 
Composite adverse neonatal outcome: abnormal birth weight (LGA or SGA) 
malformation, miscarriage, intrauterine fetal death, emergency CS due to fetal 
risk, iatrogenic prematurity, RDS, hypoglycemia, hyperbilirubinemia, and the 
postpartum pH in the umbilical artery ≤ 7.1. 
* Mann-Whitney test, ** Chi2 test
Table 5. Predictors of LGA
Analyzed parameter OR (95% OR) p
Diabetes duration [years] 0.95  (0.92–0.99) 0.02
Body weight in trimester I [kg] 0.22  (0.08–0.57) 0.00
HbA1c in trimester I [%] 1.99  (1.09–3.62) 0.00
HbA1c in trimester II [%] 0.29  (0.18–0.48) 0.01
Insulin requirement in trimester III 
(kg/body weight) 2.63 (1.05–6.63) 0.04
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glycemia is a vicious cycle that raises insulin resistance. This 
wrong habit also leads to an excessive gestational body 
weight gain and adds to dangerous changes in lipid profile. 
This way, inappropriate insulin dose also contributes to 
metabolic changes that often lead to excessive fetal growth, 
despite apparently good metabolic control [19].
An important problem during pregnancy complicated 
by pregestational diabetes is the abnormal growth of the 
fetus which can manifest as excessive (LGA) or restricted 
(SGA) growth. Excessive fetal growth is caused mainly by 
fetal hyperinsulinemia, resulting from maternal hypergly-
cemia [20]. However, studies on metabolic control dur-
ing pregnancy as a predictor of growth disorders provide 
contradictory results, whether it is more influenced by the 
average glycemia or pre- or postprandial glycemia. Some 
authors confirm that elevated HbA1c levels are a signifi-
cant risk indicator of LGA [21, 22]. Combs et al. [23] deny, 
however, the importance of average glycemia, and point 
out especially on postprandial hyperglycemia. In recent 
reports, LGA newborns are predominant in pregnancies 
complicated by mild hyperglycemia and maternal obesity, 
whereas the increased prevalence of SGA is characteristic 
for pregnancies complicated by diabetic microangiopathy, 
especially diabetic kidney disease, as well as hypertension 
and preeclampsia [24, 25]. These observations demonstrate 
the contribution of factors other than glycemia to fetal 
growth abnormalities, i.e. obesity and accompanying lipid 
disorders and the role of vascular complications. Also, in our 
cohort, we did not find any significant differences between 
the mean birth weight in the MDI-group and those of the 
CSII group Our results are consistent with the results of 
Cypryk et al. [26], who did not show the effect of type of 
insulin therapy on an occurrence of either LGA and SGA in 
their group. It should be noted, however, that in the CSII, 
the proportion of LGA was a few percent lower than in the 
MDI group, while the percentage of SGA was very similar in 
both groups although the CSII group consisted of patients 
with more complicated diabetes. The lack of significant 
differences in the incidence of growth disorders does not, 
however, make it possible to unequivocally demonstrate 
the superiority of any of the analyzed methods of intensive 
functional insulin therapy. However, due to the fact that the 
percentage of all growth disorders was lower in the CSII 
group, it seems that this model of treatment may contribute 
to a reduction in the incidence of these disorders.
In the logistic regression model, the predictors of LGA 
were: duration of diabetes, patient body weight in the first 
trimester, glycated haemoglobin in the first and second 
trimesters, and insulin requirement in the last trimester of 
pregnancy. These associations provide an additional proof 
that in an appropriately controlled pregnant woman, the 
occurrence of excessive fetal birth weight depends on many 
factors and the fact that the insulin requirement in the 
third trimester of pregnancy was the most potent predictor 
confirms the role of insulin resistance in inducing excessive 
growth. Low body weight in pregnant women seems to 
correlate with the fact that these patients often pay less at-
tention to later weight gain in pregnancy than overweight 
patients, and we know that excessive weight gain is also 
a factor inducing excessive fetal growth.
Assessment of pregnancy outcomes including newborn 
birth weight, week of delivery, and the mode of delivery, 
did not show statistically significant differences between 
the MDI and CSII groups, which is in agreement with the 
results of other authors [18, 27–29]. The timing and mode of 
delivery in patients with T1DM remains a subject to exten-
sive discussion. In the absence of indications resulting from 
vascular complications, fetal macrosomia, or birth defects, 
there are no indications for scheduled cesarean section [11]. 
The situation can change completely intrapartum when 
symptoms of fetal or maternal risks can occur suddenly. Neff 
et al. showed a significant difference in the higher propor-
tion of pregnancies completed by cesarean section in CSII 
patients. However, this was a group of patients with a sig-
nificantly longer disease history and was, therefore, more 
burdened by vascular complications [30]. In our cohort, we 
did not find any significant difference in the proportion of 
physiological labours, labours with interventions, or cesar-
ean section.
Most of the available reports show no effect of the used 
therapy on the newborn status after birth [18, 26, 30, 31]. 
Tylaviya et al. [32] demonstrated that the only significant 
parameter is the Apgar score, which was higher in CSII moth-
ers. Several reasons make any epidemiological analysis of 
pregnancy outcomes in diabetic mothers challenging: first, 
CSII is a relatively new modality in diabetes treatment, and 
only limited amount of data from small cohorts of pregnant 
women is available. Second, due to a general improvement 
in antenatal care seen in the last decades in the settings 
where specific needs of pregnant women are appropriately 
addressed, some of the perinatal complications (e,g. late 
intrauterine death or intrapartum complications) became 
rare anyway. Therefore, prospective intervention trials ade-
quately powered to track rare complications in a population 
of pregnant women suffering from the disease complicating 
ca. 1% of pregnancies would be trying even if running such 
research in a frame of multicenter cooperation. In our cohort, 
we found a significantly reduced number of overall neonatal 
complications, defined as a composite adverse neonatal 
outcome, in the CSII arm. Although this difference lost sta-
tistical significance after controlling for the confounded, it 
still remains a possible relevant clinical finding. The reasons 
for this advantage should be sought in facilitated glycemic 
control with the use of insulin pump that accurately adjusts 
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the dose of both the basal insulin and the type and dose of 
prandial boluses [33]. Continuous infusion allows for a more 
flexible and stable administration of basal insulin achieving 
nocturnal and early-morning normoglycemia more effi-
ciently than long-acting insulin boluses administered with 
a pen at night. Also, reduced number of hyperglycemia 
noted in our CSII arm could suggest improved glycemic 
variability, i.e. diminished short-term glucose fluctuations 
that can translate into a better endothelial function in pla-
centa and more stable placental transfer of nutrients. All 
this contributes to the optimization of treatment and the 
achievement of better metabolic control that alleviates or 
substantially reduces potent adverse effects of hyperglyce-
mia on the fetus [18, 27, 34]. 
CONCLUSIONS
Treatment of type 1 diabetic pregnant women with 
a personal insulin pump allows for the optimization of 
therapy and precise titration of the basal insulin dose and 
the type and size of the prandial boluses.
As a result, we note a decreased incidence of hypergly-
cemia, which seems to reduce the risk of composite adverse 
neonatal outcome and early postpartum complications in 
the offspring in this group of patients.
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